Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Stake Cut by Perfromance Wealth Partners LLC

Perfromance Wealth Partners LLC reduced its holdings in Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 41.0% in the 4th quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,726 shares of the biotechnology company’s stock after selling 1,200 shares during the period. Perfromance Wealth Partners LLC’s holdings in Sarepta Therapeutics were worth $210,000 at the end of the most recent reporting period.

Several other hedge funds have also recently bought and sold shares of the business. MassMutual Private Wealth & Trust FSB lifted its stake in Sarepta Therapeutics by 169.6% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 248 shares of the biotechnology company’s stock worth $30,000 after acquiring an additional 156 shares in the last quarter. UMB Bank n.a. raised its stake in shares of Sarepta Therapeutics by 36.0% during the 4th quarter. UMB Bank n.a. now owns 521 shares of the biotechnology company’s stock worth $63,000 after purchasing an additional 138 shares in the last quarter. Smith Salley Wealth Management purchased a new stake in shares of Sarepta Therapeutics during the 4th quarter worth about $889,000. Park Avenue Securities LLC purchased a new stake in shares of Sarepta Therapeutics during the 4th quarter worth about $205,000. Finally, Harbor Capital Advisors Inc. raised its stake in shares of Sarepta Therapeutics by 33.4% during the 4th quarter. Harbor Capital Advisors Inc. now owns 1,706 shares of the biotechnology company’s stock worth $207,000 after purchasing an additional 427 shares in the last quarter. 86.68% of the stock is owned by hedge funds and other institutional investors.

Sarepta Therapeutics Price Performance

Shares of NASDAQ:SRPT opened at $116.79 on Wednesday. Sarepta Therapeutics, Inc. has a 1-year low of $102.15 and a 1-year high of $173.25. The firm has a market capitalization of $11.16 billion, a PE ratio of 93.43 and a beta of 0.77. The business’s 50 day moving average is $121.66 and its 200-day moving average is $128.87. The company has a current ratio of 3.84, a quick ratio of 3.03 and a debt-to-equity ratio of 0.93.

Insider Buying and Selling

In other Sarepta Therapeutics news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of Sarepta Therapeutics stock in a transaction on Thursday, December 12th. The stock was sold at an average price of $124.84, for a total value of $1,310,820.00. Following the completion of the transaction, the director now owns 22,840 shares in the company, valued at approximately $2,851,345.60. The trade was a 31.49 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Kathryn Jean Boor sold 1,636 shares of Sarepta Therapeutics stock in a transaction on Thursday, December 5th. The shares were sold at an average price of $125.55, for a total value of $205,399.80. Following the completion of the transaction, the director now owns 5,880 shares of the company’s stock, valued at approximately $738,234. The trade was a 21.77 % decrease in their position. The disclosure for this sale can be found here. 7.70% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts have recently weighed in on SRPT shares. Jefferies Financial Group started coverage on Sarepta Therapeutics in a research note on Monday, October 21st. They set a “buy” rating and a $165.00 price target for the company. Robert W. Baird cut their price target on Sarepta Therapeutics from $200.00 to $193.00 and set an “outperform” rating for the company in a research note on Thursday, November 7th. HC Wainwright reaffirmed a “sell” rating and set a $75.00 price target on shares of Sarepta Therapeutics in a research note on Wednesday, January 15th. Needham & Company LLC reissued a “buy” rating and set a $202.00 price objective on shares of Sarepta Therapeutics in a report on Tuesday, January 14th. Finally, Evercore ISI lowered their price objective on Sarepta Therapeutics from $179.00 to $170.00 and set an “outperform” rating on the stock in a report on Thursday, November 7th. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, nineteen have issued a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $178.71.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.